Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

BACKGROUND: Mean survival in cancer trials can be estimated with statistical techniques to extrapolate study survival curves. This methodology was applied to data from the VELOUR trial, where use of the novel biologic aflibercept (ziv-aflibercept in the United States) in combination with fluorouraci...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Joulain, F, Proskorovsky, I, Allegra, C, Tabernero, J, Hoyle, M, Iqbal, S U, Van Cutsem, E
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2013
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3790175/
https://ncbi.nlm.nih.gov/pubmed/24045663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.523
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky